Patients with renal anemia undergoing hemodialysis who were treated for up to 24 months with the intravenous biosimilar epoetin alfa HX575 (Binocrit) showed hemoglobin outcomes equivalent to reference epoetin alfa.
Patients with renal anemia undergoing hemodialysis who were treated for up to 24 months with the intravenous biosimilar epoetin alfa HX575 (Binocrit) showed hemoglobin (Hb) outcomes equivalent to reference epoetin alfa, according to a study published in the January 2018 issue of Clinical Nephrology.
The study (MONITOR-CKD5) is the largest and longest study of a biosimilar epoetin alfa in the hemodialysis setting. It was funded by Hexal AG (Sandoz, Novartis). Binocrit, a product of Sandoz, was approved in the European Union in 2007 for the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure, and is a biosimilar of Epogen (Amgen) and Procrit (Janssen).
Gérard London, MD, and colleagues reported that the majority of treated patients in their study were maintained within guideline-recommended target Hb ranges, and no previously unknown safety signals, including immunogenicity, were detected.
The study was carried out in 114 centers in 10 European countries; of 2086 patients enrolled in the study, 1000 completed all follow-up visits and comprised the evaluable enrollment sample. The sample was predominantly male (median age of 68 years), and almost exclusively Caucasian. The most prevalent primary chronic kidney disease etiologies included diabetic nephropathy, chronic glomerulonephritis, and renal vascular disease. Median time on dialysis was 2.1 years.
At enrollment, most patients (82.5%) had been treated with an erythropoiesis-stimulating agent, and 73.0% had adequate iron stores. At baseline, mean (± standard deviation) baseline Hb was 11.09 (±1.14) g/dL and HX575 dose 106.5 (±78.7) International Units (IU)/kg/week; at month 24, Hb was 11.25 (±1.19) g/dL and HX575 dose was 113.0 (±102.5) IU/kg/week. Variations in mean HX575 dose and Hb over the study period were not statistically significant.
With respect to safety, 140 patients (6.7%) experienced 1 or more adverse event (AE); of these, 19 AEs (16 patients; 0.8%) were related to treatment with HX575; 148 AEs (108 patients; 5.2%) were reported as serious, including 12 events in 11 patients (0.5%) that were stated by the researchers as related to the drug. No cases of anti-epoetin antibodies or pure red cell aplasia were reported.
The researchers note that the current study demonstrates that the efficacy of intravenous HX575 in managing renal anemia in patients undergoing hemodialysis, which was established in earlier pivotal trials and validated in follow-on studies, translates into real-world effectiveness, with safety evidence extending up to 2 years. The study shows that Hb concentrations and treatment-response indicators converged across 3 critical HX575 studies, and under similar dosing regimens.
“Importantly, what our study adds is that this pattern of stable dosing and stable Hb effectiveness outcomes can be achieved sustainably for up to 24 months with HX575 under conditions of greater heterogeneity in patients, clinicians, and settings compared to the relative homogeneity that characterizes efficacy trials,” the authors said.
With the relative effectiveness and safety of HX575 established, the investigators conclude that policy, financing, and access to care issues related to the biosimilar can be addressed. “In an era of payment constraints to dialysis providers, the use of biosimilar epoetin alfa can generate significant savings.”
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.